Abstract:A growing number of studies have demonstrated the role of post-translational modifications of proteins, particularly acetylation, in human diseases including neurodegenerative and cardiovascular diseases, diabetes, cancer, and in aging. Acetylation of mitochondrial proteins has been shown to be involved in the pathogenesis of cardiac diseases such as myocardial infarction (ischemia-reperfusion) and heart failure. Indeed, over 60% of mitochondrial proteins contain acetylation sites, and most of these proteins are involved in mitochondrial bioenergetics. Mitochondrial non-enzymatic acetylation is enabled by acetyl-coenzyme A abundance and serves as the primary pathway of acetylation in mitochondria. Hence, regulation of enzymatic deacetylation becomes the most important mechanism to control acetylation/deacetylation of mitochondrial proteins. Acetylation/deacetylation of mitochondrial proteins has been regarded as a key regulator of mitochondrial metabolism and function. Proteins are deacetylated by NAD+-dependent deacetylases known as sirtuins (SIRTs). Among seven sirtuin isoforms, only SIRT3, SIRT4, and SIRT5 are localized in the mitochondria. SIRT3 is the main mitochondrial sirtuin which plays a key role in maintaining metabolic and redox balance in the mitochondria under physiological and pathological conditions. SIRT3 regulates the enzymatic activity of proteins involved in fatty acid oxidation, tricarboxylic acid cycle, electron transport chain, and oxidative phosphorylation. Although many enzymes have been identified as targets for SIRT3, cardiac-specific SIRT3 effects and regulations could differ from those in non-cardiac tissues. Therefore, it is important to elucidate the contribution of SIRT3 and mitochondrial protein acetylation/deacetylation in mitochondrial metabolism and cardiac dysfunction. Here, we summarize previous studies and provide a comprehensive analysis of the role of SIRT3 in mitochondria metabolism and bioenergetics under physiological conditions and in cardiac diseases. In addition, the review discusses mitochondrial protein acetylation as a potential target for cardioprotection.

Study on the Correlation of SIRT3 with Metabolic Syndrome and Myocardial Hypertrophy

The relationship of SIRT3 with cellular metabolism and cardiovascular diseases

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

Sirt3 is a Novel Target to Treat Sepsis Induced Myocardial Dysfunction by Acetylated Modulation of Critical Enzymes Within Cardiac Tricarboxylic Acid Cycle

SIRT3: A New Regulator of Cardiovascular Diseases

Advances on Sirt3 in cardiovascular diseases and longevity

Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease

Research progress on the role of Sirt3 in myocardial infarction

SIRT1 in metabolic syndrome: where to target matters.

Mitochondrial Sirtuins in cardiometabolic diseases.

A review on SIRT3 and its natural small molecule activators as a potential Preventive and therapeutic target

Mitochondrial Sirtuin 3: New emerging biological function and therapeutic target

Sirtuin-3-Mediated Cellular Metabolism Links Cardiovascular Remodeling with Hypertension

SIRT3 involved in protecting heart by regulating mitochondrial protein deacetylation

Novel Role of the SIRT1 in Endocrine and Metabolic Diseases

Advances in SIRT3 involvement in regulating autophagy-related mechanisms

Acetylation of Mitochondrial Proteins in the Heart: The Role of SIRT3

NMNAT3 is Involved in the Protective Effect of SIRT3 in Ang II-induced Cardiac Hypertrophy

SIRT3 Deficiency Exacerbates P53/parkin‑mediated Mitophagy Inhibition and Promotes Mitochondrial Dysfunction: Implication for Aged Hearts

Advances in the Role of SIRT3-mediated Mitochondrial Function and Metabolic Regulation in Diabetes Mellitus Type 2

Sirtuin 3 and mitochondrial permeability transition pore (mPTP): A systematic review